Regeneron receives $1 billion upfront and could get up to $7 billion more if milestones are met. It must also pay half of new program costs and share future profits equally, but the upfront payment and added drug candidates favor the company.
The cash gives Regeneron money before the new treatments reach patients. More payments depend on development, approval, and sales milestones. Regeneron will also cover half the costs and split profits, but the upfront payment and added drug candidates favor the company.
Sanofi pays $1 billion upfront and half of new program costs, then shares future profits equally. It gains four drug candidates, while Dupixent's current profit split stays unchanged, so the deal does not clearly shift its outlook.
Follow Regeneron Pharmaceuticals Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for REGN